Lisa Mahnke

TL;DR: Treatment with avelumab was associated with durable responses, most of which are still ongoing, and was well tolerated; hence, a Velumab represents a new therapeutic option for advanced Merkel cell carcinoma.

TL;DR: M7824 has a manageable safety profile in patients with heavily pretreated advanced solid tumors and early signs of efficacy are encouraging, and multiple expansion cohorts are ongoing in a range of tumors.

TL;DR: Overall, the literature on chemotherapy in patients with metastatic MCC is sparse, with most studies being case series/reports, and there is a need for novel agents that can induce durable responses in metastatics MCC.

TL;DR: The low ORR and brief DOR underscore the need for novel therapies in second-line and later chemotherapy and first-line chemotherapy.

TL;DR: The low response rates and limited durability confirm previous reports of the ineffectiveness of second-line or later chemotherapy in patients with metastatic MCC and provide a benchmark for assessing clinical benefit of new treatments.